For US Healthcare Professionals Only
Important Information Related to Your Request:
The material below is provided in response to your specific search for information on UCBCOMPASS® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.
Safety and efficacy with zilucoplan in pediatric patients have not been established. Zilucoplan is indicated by the US Food and Drug Administration for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.